SFCA3007: Significantly Greater Improvements in Pre-Dose FEV1 Seen with FSC250/50 vs. SAL50

Endpoint

(1%)

(11%)

(17%)

(9%)

*

*P=0.012 vs SAL

? FEV1 (ml)

Previous slide

Next slide

Back to first slide

View graphic version